North American Acute Ischemic Stroke Diagnosis & Treatment Market

North America Acute Ischemic Stroke Treatment & Diagnosis Market Size  (2022 to 2027)

The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in North America was worth USD 796.21 million in 2022 and estimated to be growing at a CAGR of 6.2%, to reach USD 1075.60 million by 2027.

The increasing number of patients with acute ischemic stroke and technological innovations in diagnostics (Neurological CT scans and MRI scans) are the main factors driving the market growth. In 2019, the prevalence of ischemic stroke was over 2%, with over 15 million diagnoses made across the globe. According to the latest report by the American Heart Association, the incidence of stroke in the United States was 3.5% in 2020, and these numbers will increase further to reach 3.89% by 2030.  In addition, compared to 1999, a 2-3-fold increase in the number of neurologists was observed in all countries. As a result, the increasing incidence of stroke with more episodes is becoming very common, contributing to the market's growth.

According to the World Health Organization (WHO), 15.69 million people suffer from stroke each year worldwide. As a result, 5.55 million die, and another 5.21 million are permanently disabled. Stroke is the third leading cause of death in the United States, with more than 140,500 people dying each year from stroke in the United States. The main risk factors that increase the risk of stroke among US citizens are high blood pressure, smoking, diabetes, high cholesterol, sedentary lifestyles, and lack of exercise. High blood pressure contributes to over 13 million strokes worldwide.

The main obstacle to developing the market for the diagnosis and treatment of acute ischemic stroke is the clinical trial, which includes prolonged trials of the drug after the onset of the stroke. In addition to the initial investment cost for purchasing the imaging equipment is around $ 8.56 million each year. These factors play a negative role in the studied market growth.

This research report on the North American acute ischemic stroke treatment & diagnosis market has been segmented and sub-segmented into the following categories:

By Diagnostic Type:

• Computed Tomography
• Magnetic Resonance Imaging
• Ultrasound
• Cerebral Angiography
• Nuclear Imaging

By Surgery Type:

• Carotid Endarterectomy
• Angioplasty
• Endovascular Mechanical Thrombectomy

By Country:

• United States
• Canada
• Rest of North America

The acute ischemic stroke diagnosis and treatment market in the United States is growing at a significant CAGR in the North American region during the forecast period. The United States leads the North American regional market, owing to the increasing prevalence of stroke. Stroke is the leading cause of long-term disability and the fifth leading cause of death among Americans. According to the CDC, about 795,500 people in the United States have a stroke each year. About 85% of these 795,000 patients are diagnosed with acute ischemic stroke. This has resulted in an increasing demand for accurate diagnosis and treatment.

The Canadian acute ischemic stroke diagnosis and treatment market is forecasted to grow at a healthy CAGR from 2022 to 2027. Factors such as the increased prevalence of chronic diseases and acute ischemic stroke complications potentially favor the market in Canada. In addition, according to an estimate by the World Health Organization, approximately 18 million people die each year from cardiovascular disease. The higher death rates associated with stroke underscore the imminent need for diagnosis. Hence, the increasing pressure for rapid diagnosis has significantly contributed to the market's growth.

KEY MARKET PLAYERS:

Companies playing a promising role in the North American acute ischemic stroke treatment & diagnosis market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.